165 related articles for article (PubMed ID: 37406395)
1. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
Shu Y; Tang Y; Ding Y; Zhang Q
Int Immunopharmacol; 2023 Sep; 122():110543. PubMed ID: 37406395
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Li Y; Liang X; Li H; Yang T; Guo S; Chen X
Front Pharmacol; 2022; 13():906956. PubMed ID: 35928269
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
Li Y; Liang X; Li H; Chen X
Cancer; 2022 Nov; 128(22):3995-4003. PubMed ID: 36111952
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
Chen Q; Sun Q; Zhang J; Li B; Feng Q; Liu J
PLoS One; 2024; 19(3):e0295090. PubMed ID: 38437209
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma.
Zhou T; Cao Y; Wang X; Yang L; Wang Z; Ma A; Li H
Adv Ther; 2022 May; 39(5):2165-2177. PubMed ID: 35296994
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.
Shu Y; Ding Y; Li F; Zhang Q
Int Immunopharmacol; 2023 Jan; 114():109589. PubMed ID: 36700770
[TBL] [Abstract][Full Text] [Related]
8. The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China.
Meng R; Cao Y; Zhou T; Hu H; Qiu Y
Front Public Health; 2022; 10():794131. PubMed ID: 35433574
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.
Guan H; Wang C; Zhao Z; Han S
Adv Ther; 2022 Jul; 39(7):3334-3346. PubMed ID: 35644019
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
Chen S; Peng Z; Wei M; Liu W; Dai Z; Wang H; Mei J; Cheong M; Zhang H; Kuang M
BMC Cancer; 2018 Apr; 18(1):392. PubMed ID: 29621988
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.
Chee CE; Khara JS; Cheong J; Fong J; Sivanesan S; Choy JY; Hu M; Viswambaram A; Toh HC
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):631-641. PubMed ID: 38776431
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
15. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.
Zheng Z; Lin Y; Cai H
Front Public Health; 2024; 12():1356244. PubMed ID: 38562257
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B
JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.
Li W; Wan L
BMJ Open; 2023 Sep; 13(9):e074245. PubMed ID: 37751954
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China.
Wang H; Wang Y; Li L; Zhou H; Lili S; Li L; Yike S; Aixia M
Front Public Health; 2022; 10():954264. PubMed ID: 36159269
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.
Lang W; Deng L; Huang B; Zhong D; Zhang G; Lu M; Ouyang M
Clin Drug Investig; 2024 Mar; 44(3):149-162. PubMed ID: 38300386
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]